# Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation

Study · id `cardio:ct-nct06096337` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06096337](<https://clinicaltrials.gov/study/NCT06096337>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06096337

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 484 participants.

## Technical summary

Registry record NCT06096337. Randomized; no masking; primary purpose treatment. Start 2023-12-28 (actual); primary completion 2026-02-04 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 484 participants (enrolled count; ClinicalTrials.gov record NCT06096337, source copy `cardio:ctgov-nct06096337-2026-08-28`, retrieved 2026-10-26)
- Started: 2023-12-28 (actual) (ClinicalTrials.gov record NCT06096337, source copy `cardio:ctgov-nct06096337-2026-08-28`, retrieved 2026-10-26)
- Primary completion: 2026-02-04 (actual) (ClinicalTrials.gov record NCT06096337, source copy `cardio:ctgov-nct06096337-2026-08-28`, retrieved 2026-10-26)
- Completion: 2028-02-04 (anticipated) (ClinicalTrials.gov record NCT06096337, source copy `cardio:ctgov-nct06096337-2026-08-28`, retrieved 2026-10-26)
- Countries: United States; Australia; Austria; Belgium; Canada; Croatia; France; Germany; Hong Kong SAR China; Italy; Singapore; Spain; Taiwan (ClinicalTrials.gov record NCT06096337, source copy `cardio:ctgov-nct06096337-2026-08-28`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06096337-2026-08-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation
- Acronym: AVANT GUARD
- Condition: Persistent Atrial Fibrillation
- Intervention (Device): FARAPULSE™ Pulsed Field Ablation (PFA) System
- Intervention (Drug): Anti-Arrhythmic Drug (AAD): Flecainide, Sotalol, Propafenone, Dofetilide, and Dronedarone
- Lead sponsor: Boston Scientific Corporation
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Boston Scientific (`cardio:boston-scientific`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Pulsed Field Ablation as Initial Therapy for Persistent Atrial Fibrillation (`cardio:pubmed-42041224`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 6b30c2d668c651ad77aa46cb15ddffe8fab8fd7bd61d075bdb13223ba110c9a6
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
